预约演示

更新于：2025-05-07

Corneal Opacity

角膜混浊

更新于：2025-05-07

基本信息

别名

CORNEAL CLOUDING、CORNEAL OPACITY、CORNEAL OPACITY DISORDER

+ [43]

简介

Disorder occurring in the central or peripheral area of the cornea. The usual degree of transparency becomes relatively opaque.

关联

项与角膜混浊相关的药物

Tranilast

曲尼司特

靶点

TGF-β

作用机制

TGF-β抑制剂

在研机构

Juntendo University [+7]

原研机构

Kissei Pharmaceutical Co., Ltd.

在研适应症

哮喘 [+8]

非在研适应症

瘢痕 [+3]

最高研发阶段批准上市

首次获批国家/地区

日本

首次获批日期1982-06-15

Oculentum Hydrargyri Oxydi Flavi

黄氧化汞

靶点-

作用机制-

在研机构-

原研机构-

在研适应症

睑缘炎 [+3]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期1981-01-01

LSCD101

靶点-

作用机制-

在研机构-

原研机构

CLIPS SA

在研适应症-

非在研适应症

老年环 [+1]

最高研发阶段无进展

首次获批国家/地区-

首次获批日期1800-01-20

项与角膜混浊相关的临床试验

CTIS2023-506856-25-00

/ Recruiting临床2期IIT

Phase IIb, randomised, controlled, unblinded, multicentre, clinical trial to evaluate the clinical efficacy of a nanostructured fibrin-agarose artificial cornea model (NANOULCOR) in patients with severe corneal ulcers. - FIB-NAN-2023-01

开始日期2025-03-28

申办/合作机构-

NCT06695910

/ Recruiting临床4期

Modulation of the Brain Fog Scale by Eicosapentaenoic Acid Monoglycerides (MAG-EPA) in Volunteers Who Reported Suffering from Haze or Mental Fatigue on a Regular Basis. Exploratory Study (NBF-MG01).

A growing body of studies shows that omega-3s act directly in molecular signaling pathways that reduce inflammation and are thought to have a positive effect on cognitive health. Brain fog is a term that has been popularized in the medical world in the wake of the COVID-19 pandemic. A significant proportion of patients with long COVID reported having cognitive sequelae that were like fogginess. It is defined as a cognitive impairment with characteristic symptoms including problems with concentration, attention and memory, confusion, difficulty understanding what others are saying, reduced mental acuity and mental fatigue. These are episodes of reduced cognitive capacity that are not representative of the person's normal state. This condition can be caused by various factors such as stress, lack of sleep, overwork, depression, hormonal changes due to pregnancy or menopause in women, head injuries, migraine, certain diseases or viral infections, certain medications as well as substance abuse (alcohol and/or street drugs). In this study, we want to test whether omega-3 monoglycerides (MAG-EPA) can alter the cognitive health of people with brain fog.

开始日期2024-11-06

申办/合作机构

SCF Pharma, Inc.

NCT06174376

/ RecruitingN/A

A Prospective, Multi-Center, Early Feasibility Study to Assess Clinical Outcomes of the GORE Synthetic Cornea Device in Patients With Loss of Corneal Clarity

Study objective is to evaluate the initial safety and effectiveness of the GORE Synthetic Cornea Device in the treatment of loss of corneal clarity in patients who are candidates for corneal transplantation

开始日期2024-08-19

申办/合作机构

W. L. Gore & Associates, Inc.

100 项与角膜混浊相关的临床结果

登录后查看更多信息

100 项与角膜混浊相关的转化医学

登录后查看更多信息

0 项与角膜混浊相关的专利（医药）

登录后查看更多信息

6,358

项与角膜混浊相关的文献（医药）

2025-12-31·Veterinary Quarterly

Developing a novel TaqMan qPCR assay for optimizing Salmonella Pullorum detection in chickens

Article

作者: Li, Yan ; Wang, Haijian ; Kehrenberg, Corinna ; Yu, Longhai ; Wang, Hao ; Müller, Anja ; Kang, Xiamei ; Yue, Min

Salmonella Pullorum, the causative agent of pullorum disease, posing a significant threat to the global production of poultry meat and eggs. However, existing detection methods have substantial limitations in efficiency and accuracy. Herein, we developed a genomic deletion-targeted TaqMan qPCR assay for identification of Salmonella Pullorum, enabling precise differentiation from other Salmonella serovars. The assay's detection limit was 5 copies/μL of plasmid and 4 CFU/μL of bacterial DNA. Furthermore, we collected 676 chicken samples from an established infection model to compare the performance of the TaqMan qPCR assay with traditional bacterial culturing and antibody-based detection approaches. With superior sensitivity and specificity, the newly developed method detected over 80% of positive chickens, significantly outperforming the two conventional methods. Moreover, we proposed a combined framework that incorporates the advantages of TaqMan qPCR assay and antibody detection method, further enhancing the detection rate of positives to 92%. Additionally, to address the frequent aerosol contamination of amplification products in laboratory settings, we devised an easy-to-deploy anti-contamination system based on T7 exonuclease. Overall, the T7 exonuclease-assisted TaqMan qPCR assay will not only upgrade the current detection for pullorum disease, but also exemplify the feasibility of targeting specific genomic deletions for pathogen detection.

2025-12-01·Molecular Biology Reports

Molecular analysis of mucopolysaccharidosis type VI in Iranian patients; the influence of founder effect and consanguinity

Article

作者: Askarizadeh, Athena ; Kalantar, Seyed Mehdi ; Ordooei, Mahtab ; Moradi, Ali ; Mohiti-Ardakani, Javad

BACKGROUNDMucopolysaccharidosis type VI (MPS VI), also known as Manteaux-Lamy syndrome, is an autosomal recessive lysosomal storage disorder caused by deficiency of the enzyme arylsulfatase B(ARSB). This syndrome is progressive and affects many tissues and organs, leading to inflammation and scarring. The classic clinical features of Maroteaux-Lamy syndrome are significant impairment of the osteoarticular system with dysostosis multiplex, short stature and motor dysfunction. The rate at which symptoms appear and worsen can vary between affected individuals. Mutations in the ARSB gene are responsible for MPS VI. We investigated the clinical presentation and molecular basis of patients with MPS VI for the first time in Yazd province, Iran.METHODSOf the 52 people who took part in this project, there were 13 probands. Whole exome sequencing (WES) was performed in 2 of them and the nominated mutation in the ARSB (c.430G > A) was verified by Sanger sequencing in the remaining patients.RESULTSAll patients had parental consanguinity, except for one family in which the parents were unrelated. All patients were of Fars ethnicity and had characteristic phenotypes such as severe short stature, cardiac involvement, coarse facial features, and corneal opacities. Sequence analysis of the ARSB gene revealed a pathogenic homozygous missense mutation c.430G > A (p. Gly144Arg) in all patients. This type of mutation influenced the phenotypes of the severe patients.CONCLUSIONSThese results expand the genetic databases of Iranian patients with MPS VI and would be very helpful for the high-risk families to accelerate the detection of carriers and to perform prenatal testing for the disorder in this population in a cost-effective manner. There is a possibility that other unknown mutations are responsible for the disease. The decision to screen for and detect carriers of this disease at a national level is awaited. The results of the present study could be an asset for married families in part of the city of Meybod. The results offer a way for early detection of patients and carriers of the disease.

2025-07-01·Ophthalmology Science

Vision Loss and Blindness in the United States: An Age-Adjusted Comparison by Sex and Associated Disease Category

Article

作者: Eppich, Kaleb ; Blakley, Macey S ; Bugg, Victoria A ; Hartnett, M Elizabeth ; Lum, Flora ; Greene, Tom

PurposeTo evaluate differences in vision loss and blindness by disease category between men and women in the the United States (US).DesignRetrospective observational study.ParticipantsPatients (14 549 105) >50 years old with eye examination data recorded in the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) between January 1, 2018, and December 31, 2018.MethodsPatients were assigned to the vision loss cohort and categorized (mild, moderate, severe, blindness) based on the best-corrected visual acuity in the better-seeing eye. The cause of vision loss was assumed using the International Classification of Diseases, 10th Revision codes for cataract, diabetic retinopathy, age-related macular degeneration (AMD), glaucoma, retinal detachment, retinal vein occlusion, corneal opacity, or amblyopia documented in the electronic health record. The no vision loss cohort was created by subtracting the vision loss cohort from the 2018 total IRIS Registry database.Main Outcome MeasuresPrimary analyses provided age-adjusted prevalence ratios (PRs) for vision loss conditions for women and men within the vision loss cohort relative to the 2018 US census. Secondary analyses computed age-adjusted PRs for women and men for the same conditions relative to the IRIS Registry.ResultsThe age-adjusted PR of vision loss in women versus men when comparing our vision loss cohort relative to the US census was 1.28 (95% confidence interval, 1.27, 1.29) for mild vision loss, 1.29 (1.28, 1.30) for moderate vision loss, 1.35 (1.32, 1.38) for severe vision loss, and 1.54 (1.49, 1.59) for blindness. However, these differences were attenuated when age-adjusted prevalences were computed relative to those who were seen in 2018 in the IRIS Registry database. In women, the prevalence of vision loss associated with cataract and AMD was increased in both analyses, while men had a higher prevalence of vision loss associated with retinal detachment in both analyses.ConclusionsWomen in the US are more likely to be diagnosed with vision loss at an IRIS Registry practice compared with men, based on clinical presentations relative to the US census. However, this finding is partly driven by the higher rates at which women presented to ophthalmic practices in both the vision loss cohort and no vision loss cohort. The age-adjusted prevalence for vision loss associated with cataract and AMD was higher in women when utilizing both the US census and the 2018 IRIS Registry database as the denominator, which suggests that a true difference in prevalence is present. The same is true for an increase in the age-adjusted relative risk for vision loss associated with retinal detachment in men. These findings warrant further study.Financial DisclosuresProprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

项与角膜混浊相关的新闻（医药）

2025-04-15

·梅斯医学

角膜自带“雾面美瞳”！25岁男子浮肿尿浊，家族三代男性怪病缠身，竟是近亲结婚引发的遗传代谢病！

25岁的阿杰（化名）从小就被同学笑称“自带美瞳”——他的双眼角膜像蒙了一层磨砂玻璃，透着朦胧的灰蓝色光泽。可这“免费美瞳”背后却是噩梦：半年前，他的双腿肿得像注水的海绵，尿液浑浊如隔夜奶茶，一查竟是尿蛋白超标6倍，血肌酐飙到152μmol/L（肾功能告急）！更诡异的是，他的血液静置后竟分层成“鸡尾酒”：上层浮着乳白色油脂，下层暗红黏稠。医生盯着他的角膜惊叹：“这哪是美瞳？是胆固醇结晶在眼球开派对！”图1 患者眼角膜可见环状浑浊真相大白接诊医生为阿杰做了详细的检查，患者临床主要表现有浮肿伴蛋白尿，血肌酐升高，合并增生性贫血，这些症状在肾脏病患者中均为常见表现。而角膜出现特殊的环状浑浊以及血清HDL-C显著降低，追问病史发现患者父母为近亲结婚，考虑到患者存在LCAT缺乏的可能。于是病理上进一步完善脂蛋白染色，证实患者肾小球内Apo B及Apo E脂质均为强阳性，并进一步比较沉积部位与形式，综合考虑患者IgM为脂质沉积所导致的非特异性染色，而查阅文献报道LCAT患者肾组织C3沉积呈阳性，同时亦有文献报道提示LCAT患者肾小球基底膜可能出现空泡变性，并进一步完善患者相关基因检查后最终确诊为家族性LCAT缺乏症（FLD）。图2 患者及父母基因检测结果什么是FLD？卵磷脂胆固醇酰基转移酶（LCAT）缺乏症是一种罕见的遗传性脂质代谢疾病，其导致的家族性LCAT缺乏症（FLD）和鱼眼病以角膜混浊和低水平的高密度脂蛋白胆固醇（HDL-C）为共同特征。LCAT缺乏症是一种罕见的常染色体隐性遗传性疾病，全球范围内报道的病例总数仅有数百例。国内以肾脏损害为主的报道仅2篇共3例。LCAT缺乏症由于位于人第16号染色体长臂q22上 LCAT基因发生突变引起，其特征在于LCAT酶活性的完全或部分缺失。当LCAT功能受损时，HDL的代谢过程会受到阻碍，导致血脂水平异常，并可能引发一系列并发症。临床表现FLD的临床表现主要包括角膜混浊、溶血性贫血、低HDL-C水平、蛋白尿和慢性肾脏疾病。1.角膜混浊通常在儿童或青少年时期出现，常为该病的首发症状，是由于缺乏LCAT活性导致未酯化胆固醇在角膜基质中积累，引起角膜透明度降低，严重时可能需要进行角膜移植。2.FLD患者还常伴有低HDL-C水平，这是因为LCAT在HDL的成熟过程中起着关键作用，其缺乏导致胆固醇酯化受阻，相应的游离胆固醇在血浆中累积，导致极低密度脂蛋白和低密度脂蛋白增多。3.溶血性贫血也是FLD的一个常见特征，由于红细胞膜上脂质沉积导致的溶血，使得红细胞寿命缩短，引起正色素性溶血性贫血。4.慢性肾脏病是该疾病最为严重和关键的临床表现，异常脂质在肾小球和肾小管的积聚导致肾脏损伤，早期可能出现少量蛋白尿，但随着病情的进展，可发展到大量蛋白尿，表现为肾病综合征，肾功能逐渐减退进入终末期。治疗目前，FLD的治疗主要依赖于对症支持治疗，包括使用ACEI/ARB类降压药物、降脂药物和抗血小板治疗等来控制症状和延缓疾病进展，然而，这些治疗方法的效果并不理想。近年来，FLD治疗领域出现了一些新兴的治疗策略。其中，重组人LCAT替代疗法展现了极大的潜力。此外，目前已开发出一种人LCAT的激动抗体以及小分子激活剂，有望能提高部分FLD患者残留的LCAT活性，为治疗提供新的策略。参考资料：1.程城，徐尚泽，张璐璐,等. 家族性卵磷脂胆固醇酰基转移酶缺乏症2例. 中国临床案例成果数据库，2024，06(01):E2292-E2292.2.左科，成水芹，陈文萃,等. 家族性卵磷脂胆固醇酰基转移酶缺乏症1例. 中国临床案例成果数据库，2023，05(01):E00132-E00132.来源 | 梅斯医学编辑 | wanny神经系统罕见病交流群↓点击下方“阅读原文”，下载梅斯医学APP吧！

临床研究

2024-11-21

·echemi

Japan Uses iPSC Cell Sheets for the First Time to Treat Corneal Diseases

On November 7, 2024, researchers from Osaka University published a research paper entitled "Transplantation using Induced pluripotent stem cell-derived corneal epithelial cell tablets: a single-arm, open-label, first-in-human intervention study in Japan" in The internationally renowned medical journal The Lancet. This clinical study is the first in the world to use corneal epithelial cell tablets (iCEPS) derived from human induced pluripotent stem cells (iPSC) to repair corneas in patients with visual impairment due to limbal stem cell deficiency (LSCD). The results of the study show that this new type of regenerative therapy is safe and helps to improve patients' vision. The research team plans to conduct larger clinical trials to gain a deeper understanding of the treatment's efficacy. In this study, ophthalmologist Kohji Nishida and his team at Osaka University used induced pluripotent stem cell (iPSC) technology to treat limbal stem cell deficiency (LSCD). The team took blood cells from a healthy donor and reprogrammed them into IPscs, which were then transformed into a thin, transparent sheet of oval corneal epithelial cells. During the study, the research team recruited two male and two female patients, aged 39 to 72 years, all with binocular limbal stem cell deficiency (LSCD). The team first removed the scar tissue covering one of the patient's eyes, then stitched human IPSC-derived corneal epithelial cell sheets (iCEPS) and fitted the patient with flexible protective contact lenses. At the 52nd week of follow-up, secondary measures of the clinical trial showed improvement in disease staging, improved corrected distant vision, and reduced corneal opacity in all treated eyes. Although one patient experienced a slight regression in vision improvement over the one-year monitoring period, the improvement was sustained in the remaining three patients.

细胞疗法临床结果临床研究

2024-10-31

·医药地理

【凤采鸾章·博文集】新生儿重症监护高危儿脑损伤的多因素风险评估与分析

新生儿重症监护高危儿脑损伤的多因素风险评估与分析黄道丹1,2，何国华2 ，朱敏1*，赵晓科1 ，阚清3 ，孙子家 1 (1. 南京医科大学附属儿童医院康复医学科，江苏南京 210008；2. 芜湖市第二人民医院儿科，安徽芜湖 241000；3. 南京医科大学附属儿童医院新生儿科，江苏南京 210008) 引用黄道丹, 何国华, 朱敏, 等. 新生儿重症监护高危儿脑损伤的多因素风险评估与分析[J]. 世界临床药物, 2024, 45(09): 967-971. DOI:10.13683/j.wph.2024.09.012. 作者简介黄道丹，副主任医师，研究方向：新生儿重症诊治。通信作者：朱敏，博士，副教授，硕士生导师，主任医师，研究方向：小儿脑瘫、精神发育迟滞、语言发育迟缓、遗传代谢性疾病诊治。基金项目：国家自然科学基金(81401864)；江苏省科教强卫青年人才(QNRC2016089)；江苏省妇幼保健协会科研项目(FYX201907)；南京市卫健委一般性课题(YKK19108) 摘要目的探讨新生儿重症监护病房 (neonatal intensive care unit，NICU) 高危儿脑损伤的危险因素。方法选择芜湖市第二人民医院 2019 年 3 月至 2023 年 3 月收治的 NICU 高危儿 655 例作为研究对象，根据是否发生脑损伤将其分为脑损伤组 (n ＝ 131) 和无脑损伤组 (n ＝ 524)。监测并记录两组基线资料、胎儿宫内窘迫 (fetal distress in uterus，FDIU)、分娩方式、机械通气 (mechanical ventilation，MV)、辅助生育技术、脑源性神经营养因子 (brain-derived neurotrophic factor，BDNF)、 25 羟基维生素 D[25 hydroxyvitamin D，25(OH)D] 等。以单因素分析、logistic 回归分析方法分析影响 NICU 高危儿脑损伤的危险因素。结果较无脑损伤组，脑损伤组低体质量例数、FDIU 例数、MV 例数、产前高危因素、母亲感染、BDNF 和 25(OH)D 水平均较高 (P ＜ 0.05)。Logistic 回归分析示，低体质量、FDIU、MV、产前高危因素、母亲感染、BDNF、 25(OH)D 是影响 NICU 高危儿脑损伤的危险因素 (P ＜ 0.05)。结论低体质量、FDIU、MV、产前高危因素、母亲感染、 BDNF、25(OH)D 是影响 NICU 高危儿脑损伤的危险因素。在考虑上述因素基础上，在临床中可有针对性地防控干预，帮助降低脑损伤发生风险。关键词新生儿重症监护病房；高危儿；脑损伤；危险因素章节导览 1 资料与方法 1.1 病例纳入 1.2 研究方法 1.3 统计学方法 2 结果 2.1 人口学特征 2.2 脑损伤患儿疾病种类及 NICU 高危儿脑损伤单因素分析 2.3 NICU 高危儿脑损伤危险因素分析文章节选新生儿重症监护病房 (neonatal intensive care unit，NICU) 高危儿指已经或可能发生危重疾病而需监护的新生儿，部分可发生脑损伤，出现睡眠异常、原始反射消失等轻重不等的症状，需及时识别和治疗。新生儿因一系列潜在危险因素导致的脑损伤，可使其长期神经发育障碍，对患儿家庭和社会造成一定经济负担。血清脑源性神经营养因子(brain-derived neurotrophic factor，BDNF) 参与调节交感神经和某些感觉神经生长及分化，对发育期神经生长、分化成熟、存活期及突触发育均十分重要。在脑损伤情况下，BDNF 可有显著变化。血清 25 羟基维生素 D[25 hydroxyvitamin D，25(OH)D] 具有抑制炎症反应、增强免疫系统功能、预防心血管疾病等作用。因此，这两项指标在新生儿脑损伤防治中可能发挥重要作用。多因素风险评估可综合考察高危儿脑损伤潜在危险因素，早期识别有较高脑损伤风险者，常包括分娩过程并发症、新生儿出生时生理指标等。现探讨 NICU 高危儿脑损伤危险因素，旨在帮助医疗人员制定有针对性的监护和干预措施，研发新的治疗策略，报道如下。聚焦药物综合评价促进临床合理用药请看《世界临床药物》！本刊为月刊，大16开。邮发代号4-302，全国各地邮局均可订阅。定价：26元，全年312元。订阅电话：021-62790477-751 订阅传真：021-62473200 订阅邮箱：guohx@pharmadl.com END 如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001

临床研究